Multichannel cochlear implants in children: an overview of experimental and clinical results at the University of Melbourne [Opening Lecture]

Abstract

During the last decade there has been great progress in the clinical management of profound, postlinguistically deafened adults through the use of multichannel cochlear implants. The device developed by The University of Melbourne in association with Cochlear Pty Ltd, electrically stimulates selective regions of the auditory nerve using an array of 22 platinum (Pt) electrodes located in the scala tympani. Its development followed basic experimental studies and the development and evaluation of a prototype device in the 1970's. Following safety studies and a successful clinical trial, the Melbourne/Cochlear multichannel implant was approved for use in adults by the United States Food and Drug Administration (FDA) in 1985. More than 3000 patients throughout the world have since been implanted with this device, many being able to understand a significant amount of unfamiliar, connected speech without lipreading Following miniaturization of the implant, it became suitable for use with children. In 1990, after additional biological safety and clinical investigations, the FDA approved the use of the Melbourne/Cochlear multichannel implant for profoundly deaf children above the age of two years. And in 1991, the device received the medical device implantation approval certificate from the Japanese Government. The present paper presents an overview of our recent biological safety studies and clinical experience in children, and discusses the likely future development of these devices.